硫胺素与抗坏血酸在潜在变量分析识别的脓毒症患者聚类中的差异效应
该双中心回顾性队列纳入2012年1月至2022年8月ICU收治的3465例脓毒症或脓毒症休克成人患者,基于入ICU 24小时内人口学与生理变量以潜在变量分析无监督识别出5个聚类。采用逆概率加权Cox模型比较标准治疗(2183例)、标准治疗加硫胺素(B1组,1054例)及标准治疗加硫胺素联合抗坏血酸(AA+B1组,228例)的住院死亡率。B1治疗在不同聚类中结局不同,在「重症聚类」和「呼吸聚类」中与较低的住院死亡率相关;AA+B1联合在任何聚类中均与死亡率降低无关,且在「老年聚类」中与死亡率升高相关。作者认为这些结果强化了近期试验中AA+B1联合缺乏疗效的结论,甚至对老年合并症患者的潜在危害提出担忧,而B1补充在重症和以呼吸衰竭为主的患者中与ICU生存改善相关,支持在该特定人群中进一步开展试验。
要点
- B1单药在「重症聚类」和「呼吸聚类」脓毒症患者中与较低的住院死亡率相关(逆概率加权Cox模型)。
- 硫胺素联合抗坏血酸(AA+B1)在5个聚类中均未显示与死亡率降低相关。
- AA+B1联合在「老年聚类」(老年多重合并症患者)中与住院死亡率升高相关。
- 研究基于入ICU 24小时内人口学与生理变量,以潜在变量分析无监督识别出5个聚类:重症、呼吸、老年、健康、肝脏。
- 作者认为结果支持在重症和以呼吸衰竭为主的脓毒症患者中进一步开展B1相关试验。
适用人群与场景
- 2012年1月至2022年8月入住ICU的成人脓毒症或脓毒症休克患者,共3465例。
- 标准治疗组2183例,B1组1054例,AA+B1组228例。
研究设计与关键结果
- 研究类型:双中心回顾性队列研究;样本量3465例成人脓毒症或脓毒症休克患者;分组:标准治疗组2183例、B1组1054例、AA+B1组228例。
- 采用潜在变量分析基于入ICU 24小时内人口学与生理变量无监督识别出5个聚类:重症聚类(最危重患者)、呼吸聚类(以呼吸衰竭为主)、老年聚类(老年多重合并症)、健康聚类(年轻、健康、严重程度评分低)、肝脏聚类(以肝衰竭为主)。
- 采用逆概率加权Cox模型比较住院死亡率;B1治疗在5个聚类中结局不同,在「重症聚类」和「呼吸聚类」中与较低的住院死亡率相关。
- 硫胺素联合抗坏血酸在任何聚类中均与死亡率降低无关,但在「老年聚类」中与死亡率升高相关。
证据类型、等级与局限
- 证据类型:双中心回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,这些结果强化了近期试验中AA+B1联合缺乏疗效的结论,甚至对老年合并症患者的潜在危害提出担忧。
- 作者认为,B1补充在重症和以呼吸衰竭为主的患者中与ICU生存改善相关,支持在该特定人群中进一步开展试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Thiamine and ascorbic acid have been proposed to mitigate the devastating consequences of sepsis and septic shock. To date, randomized controlled trials have failed to demonstrate a benefit of these therapies and heterogeneity of treatment effect is suspected. In this study, we aimed at assessing the heterogeneity of treatment effect of thiamine (B1) and the combination of B1 plus ascorbic acid (AA + B1) in critically ill patients with sepsis.
METHODS: We conducted a bi-centric retrospective cohort study. All adult patients admitted to the ICU with sepsis or septic shock between January 2012 and August 2022 were included. Patient clusters were identified using latent variable analysis based on demographics and physiological variables obtained within 24 h of admission. Within each cluster and using inverse probability weighted Cox models, we compared in-hospital mortality between patients who received standard treatment (control), standard treatment plus B1 (B1 group), and standard treatment plus a combination of thiamine and ascorbic acid (AA + B1 group).
RESULTS: A total of 3465 septic patients were included, 2183, 1054 and 228 in the standard, B1 and AA + B1 groups respectively. Five clusters of patients were identified in an unsupervised manner. The "Cluster Severe" included the most severely ill patients, the "Cluster Resp" patients presented with predominantly respiratory failure, the "Cluster Old" included elderly patients with multiple comorbidities, the "Cluster Fit" patients were young, healthy with low severity indices and "Cluster Liver" included patients with predominant liver failure. B1 treatment was associated with different outcomes across the five clusters. It was associated with a lower in-hospital mortality in the "Cluster Severe" and "Cluster Resp". On the other hand, the combination of thiamine and ascorbic acid was not associated with reduced mortality in any cluster but an increased mortality in"Cluster Old".
CONCLUSIONS: These results reinforce the lack of efficacy of the combination of AA + B1 reported in recent trials and even raise concerns about potential harm in older patients with comorbidities. On the contrary, we reported improved ICU survival associated with B1 supplementation in the most severe patients and those with predominant respiratory failure, supporting the need for further trials in this specific population.
参考来源
- Legouis D, Monard C, Ourahmoune A, et al. Differential effects of thiamine and ascorbic acid in clusters of septic patients identified by latent variable analysis. Crit Care. 2024. PMID: 39614357. doi:10.1186/s13054-024-05188-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。